8th Jan 2016 07:54
LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that it has identified a clinical candidate in cancer through its research agreement with Cardiff University, and it plans to file a investigational new drug application for the compound in 2016.
It expects to move the drug candidate, CB1, into clinical trials before the end of the year.
Tiziana said its original research agreement with Cardiff University, focused on developing Bcl-3 inhibitors as potential drugs to treat cancer, has been expanded to include an additional research program focused on the eradication of breast cancer stem cells through inhibition of a protein known as c-FLIP.
"Our partnership in the development of this unique molecule CB1 is an excellent example of how biotechnology companies, working collaboratively with cutting-edge prestigious research institutions such as Cardiff University, can create life changing drugs and further promote research into difficult-to-treat diseases," said Chief Operating Officer Jim Tripp in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
TILS.L